# Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

> **NCT06547216** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Avidity Biosciences, Inc.** · enrollment: 84 (estimated)

## Conditions studied

- FSHD
- FSHD1
- FSHD2
- FMD
- FMD2
- Fascioscapulohumeral Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy Type 1
- Fascioscapulohumeral Muscular Dystrophy Type 2
- Dystrophies, Facioscapulohumeral Muscular
- Dystrophy, Facioscapulohumeral Muscular
- Facioscapulohumeral Muscular Dystrophy 1
- Facioscapulohumeral Muscular Dystrophy 2
- Facio-Scapulo-Humeral Dystrophy
- Atrophy, Facioscapulohumeral
- Atrophies, Facioscapulohumeral
- Facioscapulohumeral Atrophy
- Muscular Dystrophies
- Muscular Dystrophy, Facioscapulohumeral
- FSH Muscular Dystrophy
- Landouzy Dejerine Dystrophy
- Landouzy-Dejerine Muscular Dystrophy
- Dystrophies, Landouzy-Dejerine
- Dystrophy, Landouzy-Dejerine
- Landouzy-Dejerine Syndrome
- Muscular Dystrophy, Landouzy Dejerine
- Progressive Muscular Dystrophy
- FSH

## Interventions

- **DRUG:** AOC 1020

## Key facts

- **NCT ID:** NCT06547216
- **Lead sponsor:** Avidity Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2030-04
- **Final completion:** 2030-06
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547216, "Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT06547216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*